We read with interest the paper by Zoller et al comparing the rate of hypophosphataemia with ferric carboxymaltose (FCM) versus ferric derisomaltose (FDI) infusions in patients with inflammatory bowel disease (IBD).1 The higher rate of hypophosphataemia following FCM replicates findings of other studies in patients with and without IBD.2 3 Iron deficiency anaemia is associated with reduced quality of life, increased hospitalisation and impairments in physical and cognitive function in patients with IBD,4 and further evidence to support decision making regarding appropriate intravenous iron replacement is welcome. The effect of FCM on markers of bone turnover, noted by Zoller and colleagues, is of particular concern, especially the persistence of raised bone-specific alkaline phosphatase (ALP) to day 70. Patients with IBD have a higher risk of osteopenia and osteoporosis due to chronic inflammation, steroid use and nutritional deficiencies.5 Given that the …

中文翻译：

---

羧基麦芽糖铁和脱异麦芽糖铁引起的低磷酸盐血症：案件已结，但问题仍然存在

我们饶有兴趣地阅读了 Zoller 等人发表的论文，比较了炎症性肠病 (IBD) 患者输注羧基麦芽糖铁 (FCM) 与去异麦芽糖铁 (FDI) 的低磷酸血症发生率。1 FCM 后低磷酸血症发生率较高，重复了其他研究的结果对患有和不患有 IBD 的患者进行的研究。2 3 缺铁性贫血与 IBD 患者的生活质量下降、住院时间增加以及身体和认知功能受损有关，4 欢迎进一步的证据来支持有关适当静脉补铁的决策。 Zoller 及其同事指出，FCM 对骨转换标志物的影响尤其值得关注，尤其是骨特异性碱性磷酸酶 (ALP) 升高持续到第 70 天。 IBD 患者因骨质减少和骨质疏松症的风险较高慢性炎症、类固醇使用和营养缺乏。5 鉴于……